The White House today announced landmark drug pricing agreements with Eli Lilly and Company and Novo Nordisk to lower the ...

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook ...

Macter International Limited (PSX: MACTER) has launched Semaglutide in Pakistan in Pre-Filled Syringe (PFS) and Pre-Filled ...

Middle-class Indians trying to lose weight are embracing drugs such as Mounjaro, which is also used to treat diabetes in a ...

Demand for popular weight loss drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) has long outpaced supply, forcing many patients with obesity to visit compounding pharmacies to get ...

Novo Nordisk partners with Emcure to promote Wegovy, following Eli Lilly's recent collaboration with Cipla for tirzepatide in ...

People are trying mini doses of GLP-1 drugs to lose weight or maintain weight loss, but doctors urge caution, calling the ...

The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access ...

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra, the second ...